Advised Lixis SA on its sale to global pharma inspection company SEA Vision
Advised on the cross-border sale of pharmaceutical quality control company Lixis, to SEA Vision, a global leader in pharmaceutical inspection systems. Terms of the transaction were not disclosed.
SEA Vision is an Italian company specializing in vision and track-andtrace systems for the pharmaceutical industry, with a consolidated turnover of €60 million.
Lixis is an Argentinian company with over 17 years of experience in pharmaceutical vision, control and track-andtrace systems. The operational synergies between the companies will enable SEA Vision to become the leading group providing both software and hardware in its target market in Latin America, with a local workforce of 70 professionals.
Lixis has already been collaborating with SEA Vision in the Brazilian market through the São Paulo-based subsidiary SEA Vision Latin America (SVLA).
IMAP Argentina, led by Pablo Teubal and Pedro Querio, acted as exclusive financial advisor to Lixis.